Fulminant invasive pulmonary mucormycosis with <i>Rhizopus oryzae</i> in a patient with severe aplastic anaemia and common variable immunodeficiency

Scheven, Ruth von; Lebiedz, Pia; Spieker, Tilmann; Uekoetter, Andreas; Berdel, Wolfgang E.; Keßler, Torsten

doi:10.1111/j.1439-0507.2011.02119.x

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…or Scedosporium spp. whose incidence is also thought to be increasing . The diagnostic gold standard comprising conventional culture and/or histology has low sensitivity and/or specificity rates in immunocompromised patients and results are only available after considerable delay .…”

Section: Introductionmentioning

confidence: 99%

Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA‐microarray from primary clinical samples

Boch

Reinwald

Postina

et al. 2015

Mycoses

View full text Add to dashboard Cite

The increasing incidence of invasive fungal diseases (IFD), most of all invasive aspergillosis (IA) in immunocompromised patients emphasises the need to improve the diagnostic tools for detection of fungal pathogens. We investigated the diagnostic performance of a multifungal DNA-microarray detecting 15 different fungi [Aspergillus, Candida, Fusarium, Mucor, Rhizopus, Scedosporium and Trichosporon species (spp.)] in addition to an Aspergillus specific polymerase chain reaction (PCR) assay. Biopsies, bronchoalveolar lavage and peripheral blood samples of 133 immunocompromised patients (pts) were investigated by a multifungal DNA-microarray as well as a nested Aspergillus specific PCR assay. Patients had proven (n = 18), probable (n = 29), possible (n = 48) and no IFD (n = 38) and were mostly under antifungal therapy at the time of sampling. The results were compared to culture, histopathology, imaging and serology, respectively. For the non-Aspergillus IFD the microarray analysis yielded in all samples a sensitivity of 64% and a specificity of 80%. Best results for the detection of all IFD were achieved by combining DNA-microarray and Aspergillus specific PCR in biopsy samples (sensitivity 79%; specificity 71%). The molecular assays in combination identify genomic DNA of fungal pathogens and may improve identification of causative pathogens of IFD and help overcoming the diagnostic uncertainty of culture and/or histopathology findings, even during antifungal therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA‐microarray from primary clinical samples

Boch

Reinwald

Postina

et al. 2015

Mycoses

View full text Add to dashboard Cite

show abstract

“…Despite the risk of renal toxicity, amphotericin B (1–1.5 mg/kg/day) remains the gold-standard antifungal agent used against mucormycosis. Oral posaconazole is also recommended, but these two types of drugs are often ineffective without surgical intervention ( 9 , 10 , 30 – 32 ). Voriconazole is ineffective against mucormycosis ( 33 ).…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, patients in an iron overload state, including those individuals undergoing deferoxamine chelation therapy, are uniquely predisposed to mucormycosis ( 9 ). Only 6.25% patients do not have any underlying risk factor ( 10 , 11 ). In patients with hematological malignancies, mucormycosis most commonly affects the lungs (58–81%) ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

Pulmonary mucormycosis: A case report and review of the literature

et al. 2016

View full text Add to dashboard Cite

The current study reports the case of a 15-year-old male who presented to The First Affiliated Hospital of Soochow University (Suzhou, Jiangsu, China) with a 3-day history of anergy and epistaxis. The patient was diagnosed with T-cell acute lymphoblastic leukemia according to the results of a bone marrow examination and received chemotherapy. During the agranulocytosis period, the patient developed pneumonia of the right upper lung (RUL). Once complete remission was achieved, the patient underwent a lobectomy of the RUL, together with amphotericin B therapy, following the confirmation of pulmonary mucormycosis by the histopathological results. The patient experienced 12 months of uneventful follow-up post-surgery.

show abstract

Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome

Feng

Sun

2018

Infection

View full text Add to dashboard Cite

show abstract

Fulminant invasive pulmonary mucormycosis with Rhizopus oryzae in a patient with severe aplastic anaemia and common variable immunodeficiency

Cited by 3 publications

References 0 publications

Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA‐microarray from primary clinical samples

Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA‐microarray from primary clinical samples

Pulmonary mucormycosis: A case report and review of the literature

Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome

Contact Info

Product

Resources

About